Melanoma genetics study in Taiwan
Part of Cancer clinical trials.
This study looks at genetic changes in melanoma tumors to better understand the disease. It may help find the best treatments for different stages of melanoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be older than 18 years.
- You must have a confirmed diagnosis of melanoma (other cancers are okay, but only melanoma treatment is recorded).
- You must be well enough to be up and about (ECOG score less than 3).
- Your melanoma could be early stage, locally advanced, or advanced/unresectable.
- You must be willing to provide a tumor sample (new or from the past 5 years).
- You must be expected to live more than 3 months and agree to regular follow-up.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study analyzes blood and tissue samples from melanoma patients to identify biological markers that could help doctors better understand and treat the disease. Researchers will examine archived tissue samples and blood work to develop improved diagnostic tools.
This trial studies whether certain gene patterns and a blood test can help predict how melanoma might behave. It is for people with a thicker melanoma (greater than 2 mm) that has not spread to lymph nodes or other parts of the body, and who are planning to have a sentinel lymph node biopsy.
This study follows adults with certain melanoma stages to better understand the disease over time. You may be asked to share tissue samples (if available) so researchers can study tumor biology and track outcomes.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This trial tests a personalized approach where doctors monitor tumor DNA in your blood to decide when to pause targeted therapy (encorafenib and binimetinib) for advanced melanoma with a BRAF mutation. The goal is to see if treatment breaks can be safe and effective.
This study looks at serial (repeated) tumour biopsies and blood samples in people with advanced melanoma. The goal is to understand biomarkers and disease changes over time, which may help improve future treatment decisions.
Hear when a new Primary Melanoma of the Extremity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.